1 cancer, but confounding by drug use needs to
be followed up.
2 er was documented in 9 of 14 eyes that could
be followed up.
3 s unclear for how long these patients should
be followed up.
4 A subset of 1,867 patients
was followed up.
5 us strains, and development of the infection
was followed up.
6 small (3-4.4 cm) or medium (4.5-5.4 cm) AAA
were followed up.
7 e 12 years, interquartile range 10-14 years)
were followed up.
8 During the study period 382 PLHIV
were followed-up.
9 Women who initiated PrEP
were followed up 1 month, 3 months, and 6 months after i
10 All patients
were followed up 1 year after cardiac arrest.
11 14 540 respondents
were followed-up 14 years later between April 3, 2007, a
12 infections who participated in MDA and could
be followed up,
207 (94%) cleared their infections, incl
13 s seen in 2017 by an on-call junior resident
were followed up (
257 patients).
14 Patients
were followed-up a median of 12.8 months.
15 ity samples of 51 223 adolescents in the USA
were followed up across eight waves from age 18 years (c
16 s who were HCV antibody-negative at baseline
were followed up after 12 months to calculate the HCV in
17 the 2900 individuals (50.1%) at risk for AMD
were followed up after 6 years (mean [SD] age, 60.7 [8.2
18 le range, 85-1200) after transplantation and
were followed up after belatacept conversion, for a medi
19 (4.9%) died in the hospital and 1405 infants
were followed up after discharge.
20 ated and had anti-spike IgG measured; 11,364
were followed up after negative antibody results and 126
21 Patients
were followed-up after 14 +/- 4 months.
22 the 93 patients who underwent treatment, 82
were followed-up after transplantation (mean duration, 7
23 rent guidelines on how these patients should
be followed up and managed.
24 Participants
were followed up and annual hospital costs and admission
25 Managers and their employees
were followed up and reassessed at 6 months after random
26 vel SNVs, including rs12616219 near TMEM182,
were followed-up and five of them (rs462779 in REV3L, rs
27 doses at 0, 1, and 6 months and participants
were followed up annually for 4 years.
28 Participants
were followed up annually over 8 years.
29 Five patients continued to
be followed up as of March 2017.
30 th a diagnosis of a cancer of interest still
being followed up at least 1 year later were identified
31 hacoemulsification with IOL implantation and
were followed up at 1 day, 1 month, 3 months, and 1 year
32 fant pairs; of these, 13557 children (79.5%)
were followed up at 16 years of age between September 20
33 All patients
were followed up at 2 years for the HRQOL analysis.
34 Patients
were followed up at 3, 6, 9, 12, 15, and 18 months after
35 Participants were assessed at baseline and
were followed up at 3, 6, and 9 months.
36 corticosteroids; 95/115 randomized patients
were followed up at 5-7 years posttransplant.
37 ggers of type 1 diabetes and celiac disease,
were followed up at 6 clinical centers in Finland, Germa
38 Patients
were followed up at 6 months and 1 year after randomisat
39 Participants
were followed up at 6-month intervals for up to 10 years
40 ruary 10, 2015, and alive at 6 months of age
were followed up at 9, 12, and 18 months.
41 ngletons in a population-based birth cohort)
were followed up at age six and half years.
42 Infants
were followed up at ages 6 (n = 2956) and 12 (n = 2872)
43 Patients
were followed up at annual clinic visits.
44 Patients
were followed up at least 2 years postoperatively.
45 Participants
were followed up at least every 6 months for incident ca
46 Participants
were followed up at least every 6 months for the composi
47 These subjects
were followed up at least for 12 months.
48 Patients
were followed-up at 2 weeks and 6 months post-ablation.
49 diate hyperglycaemia at baseline, 2100 (85%)
were followed-up at 2 years.
50 This group of patients
was followed up beginning on their 15th birthday until t
51 l practice when patients on oral antibiotics
are followed up by an established OPAT service.
52 l and structural observations presented here
are followed up by molecular-dynamics simulations and by
53 Myocardial contractility
was followed up by cardiac magnetic resonance (CMR) and
54 Disc quality
was followed up by magnetic resonance imaging.
55 ecommended antibiotic treatment and patients
were followed up by an outpatient parenteral antibiotic
56 No patients were excluded, and patients
were followed up by individual study groups.
57 Key findings
were followed up by matrix-assisted laser desorption ion
58 Participants
were followed up by monitoring death registries and by e
59 The patients
were followed up by questionnaires on urinary symptoms,
60 iplinary team at the median age of 7.9 years
were followed up by the same team 13-18 years later.
61 Children
were followed-up by medical staff every 3 months until 1
62 s of current asthma was ultimately ruled out
were followed up clinically with repeated bronchial chal
63 The patients
were followed-up clinically after ~15 years to determine
64 Patients with celiac disease should
be followed up closely for dietary adherence, nutritiona
65 All patients
were followed up (
Coma Recovery Scale-Revised) 3 months
66 All women
were followed up during pregnancy, through delivery, to
67 Patients
were followed up during the pandemic until April 30th, 2
68 ndividuals born in Denmark from 1955 to 2012
were followed up during the study period (total follow-u
69 Patients (n = 1107) who
were followed up during year 2 among 1185 patients with
70 All pregnant women aged >=15 years
were followed-up during pregnancy and the first year pos
71 Women
were followed up every 2 years until year 11.
72 Sixty-three study participants
were followed up every 6 months and 48 completed the 2-y
73 cryotherapy (n = 200) or LEEP (n = 200) and
were followed up every 6 months for 24 months with a Pap
74 Participants
were followed up every 6 months with clinical examinatio
75 Patients
were followed-up every 6 months for 3 years postoperativ
76 rom the English Longitudinal Study of Ageing
were followed-up every two years until they reported a d
77 hs, compared with no intervention, who would
be followed up for an additional 6 months (ie, to age 18
78 ndomized to brachytherapy and so treated had
been followed up for 1 year or longer, and 411 had been
79 ollowed up for 1 year or longer, and 411 had
been followed up for at least 5 years.
80 omplete and the last patient on treatment is
being followed up for safety issues.
81 ABPA status
was followed up for 1 year.
82 sk of AD in terms of incidence when exposure
was followed up for 9 years or more, and the association
83 A cohort of 770 pCIS patients
was followed up for at least 10 years.
84 The patient
was followed up for clinical and radiologic regression o
85 The cohort
was followed up for first occurrence of GWs until 31 Dec
86 In addition, the cohort
was followed-up for the onset of clinical Parkinson's di
87 Two patients
were followed up for >1 decade; one with 90 repeats rema
88 ean follow-up time of 2.9 (1-5.5) years, 173
were followed up for >=2 years, 112 were followed up for
89 ars, 173 were followed up for >=2 years, 112
were followed up for >=3 years, and 62 were followed up
90 , 112 were followed up for >=3 years, and 62
were followed up for >=4 years.
91 SD] age, 64.1 [2.9] years; 52.7% were women)
were followed up for 1 545 433 person-years (median [int
92 2015, through September 30, 2016); patients
were followed up for 1 year after discharge (final date
93 Participants
were followed up for 1 year and data from index colonosc
94 week socioeconomic intervention, of whom 231
were followed up for 1 year.
95 from December 2015 through October 2017, and
were followed up for 1 year.
96 All patients
were followed up for 1 year.
97 unctional disability and all-cause mortality
were followed up for 1,374 d (follow-up rate = 96.1%).
98 Participants
were followed up for 12 months with masked outcome asses
99 roup), or treatment as usual (TAU group) and
were followed up for 12 months.
100 ologous FMT participants at 8 weeks and they
were followed up for 12 months.
101 Outcomes
were followed up for 12 months.
102 -Participants
were followed up for 12 months.
103 Participants with cocaine use disorder
were followed up for 12 weeks after PET scanning to docu
104 Participants
were followed up for 12.5 years, with 57 incident CHD ev
105 Two hundred fifty-six patients
were followed up for 16.3+/-3.8 months.
106 dents who were 15 years or older (N = 77774)
were followed up for 2 years (2013-2014 to 2015-2016).
107 Foundation Trust in London, UK, 245 patients
were followed up for 2 years from the onset of first-epi
108 Participants
were followed up for 2 years to assess for interval canc
109 nt of Aortic Transcatheter Valve 2 Trial and
were followed up for 2 years.
110 Patients
were followed up for 2.3+/-1.1 years.
111 and contacts were interviewed, and contacts
were followed up for 21 days to identify secondary cases
112 n consisted of 5205 individuals with HIV who
were followed up for 24 031 person-years.
113 patients with small LRPs (<250 maxLCBI(4mm))
were followed up for 24 months.
114 entered the TFFU phase, of whom seven (39%)
were followed up for 24 weeks.
115 Participants
were followed up for 24 weeks.
116 ) or low-titre plasma (low-titre group), and
were followed up for 28 days from randomisation.
117 tamivir) twice a day for 5-10 days; patients
were followed up for 28 days.
118 y for 5 days, given orally, and participants
were followed up for 28 days.
119 ging Municipal Employees (FLAME) in 1981 and
were followed up for 28 years.
120 Participants
were followed up for 3 and 10 years for falls leading to
121 2 diabetes at 3 diabetes clinics in Rome who
were followed up for 3 years, a behavioral intervention
122 t visit was on August 30, 2016, and patients
were followed up for 30 days; the final follow-up visit
123 us occlusion of the left coronary artery and
were followed up for 33 days.
124 from May 30, 2011, to December 11, 2014, and
were followed up for 42 days after treatment.
125 Volunteers
were followed up for 48 weeks.
126 hospital from January 2011 to December 2014
were followed up for 5 years.
127 shed chemotherapy-induced cardiomyopathy and
were followed up for 6 months after CRT implantation.
128 acute episodes of SA (hemoglobin <=5.0 g/dL)
were followed up for 6 months after hospitalization.
129 tion of ocriplasmin or placebo treatment and
were followed up for 6 months.
130 y before the transplant surgery and patients
were followed up for 6 months.
131 the TFNT00 (n = 129) or SN60AT (n = 114) and
were followed up for 6 months.
132 Participants
were followed up for 60 months.
133 Subjects
were followed up for 7.5 years.
134 rt (20 ug, n = 201) or placebo (n = 199) and
were followed up for 72 weeks.
135 Patients
were followed up for 8 weeks (all patients) and up to 76
136 adults and 194 children), and all vaccinees
were followed up for 84 days.
137 All patients
were followed up for 90 days after surgery.
138 ventilation within 24 hours of ICU admission
were followed up for 90 days at the hospital.
139 enter, open-label study of idarucizumab, and
were followed up for 90 days for primary and secondary o
140 ed, of whom a total of 4754 (99.6%) patients
were followed up for a maximum of 12.4 years.
141 Patients
were followed up for a maximum of 15 days or until hospi
142 re of 4 points or greater (scale, 0-10), and
were followed up for a maximum of 28 days.
143 ODS: A total of 642 implants in 145 subjects
were followed up for a mean 6.4 years.
144 223 880 men and women
were followed up for a mean of 13 years (SD 6).
145 matched users of DPP-4 inhibitors; patients
were followed up for a mean of 3.3 years (SD 2.0).
146 Glaucoma patients
were followed up for a mean of 3.90 years (range, 2.03-5
147 m February 7, 2005, to January 15, 2013, and
were followed up for a mean of 4.1 years through the stu
148 We recruited 2404 adult patients with FH who
were followed up for a mean of 5.5 years (SD, 3.2 years)
149 ean [SD] age, 56.8 [8.0] years; 54.3% women)
were followed up for a median (interquartile range) of 8
150 [8 years]; 542 women [44.9%]) with COPD who
were followed up for a median 2.1 years, those in the lo
151 The exposed group
were followed up for a median of 1.8 years (IQR 0.6-4.3)
152 Patients
were followed up for a median of 10.7 years.
153 roup, and 526 in the silver shunt group) and
were followed up for a median of 22 months (IQR 10-24; 5
154 etween randomisation and Feb 28, 2017, women
were followed up for a median of 22.8 years (IQR 21.8-24
155 Participants
were followed up for a median of 23.6 years (IQR 19.6-28
156 patients assessable for activity in phase 2
were followed up for a median of 27.1 months (IQR 25.7-2
157 ticipants chose to start open-label PrEP and
were followed up for a median of 335 days (IQR 0-364).
158 58 664 patients
were followed up for a median of 4.3 years (IQR 2.1-6.4)
159 h 31, 2016, 1 222 670 patients in the cohort
were followed up for a median of 4.3 years (IQR 2.5-5.2)
160 Patients
were followed up for a median of 4.5 years.
161 Participants
were followed up for a median of 4.8 years (interquartil
162 d deviation, 72.1+/-7.7 years; 58.5% female)
were followed up for a median of 5 years.
163 Patients
were followed up for a median of 5.0 years (IQR 3.4-6.0)
164 Results A total of 646 cysts in 390 patients
were followed up for a median of 50 months (range, 12-18
165 Participants
were followed up for a median of 7 years (interquartile
166 s from debridement; patients without failure
were followed up for a median of 802 days.
167 ween May 21, 2005, and Dec 1, 2015, patients
were followed up for a median of 83 months (IQR 69-94 mo
168 rd secondary prevention pharmacotherapy, and
were followed up for a minimum of 12 months.
169 Patients
were followed up for a minimum period of 1 year.
170 justments, and specialist case reviews; they
were followed up for an additional 12 months without int
171 Eyes in the test sample
were followed up for an average of 5.3 +/- 3.3 years, wi
172 w-up started at age 1 year, and the children
were followed up for as long as 10.7 years (median, 5.5
173 with single-dose azithromycin (30 mg/kg) and
were followed up for assessment of clinical resolution.
174 d final analysis occurred after all patients
were followed up for at least 21 months.
175 The children
were followed up for at least 5 years [median 5.3 (range
176 idence of infection at the time of insertion
were followed up for at least 6 months and a maximum of
177 Patients
were followed up for at least 6 months, and remission cr
178 Children
were followed up for clinical malaria from birth until 4
179 k (n=32 919) and Sweden (n=63 528), patients
were followed up for CRC incidence and CRC mortality bet
180 Children (n = 373)
were followed up for ever asthma until the age of 10.5 y
181 erwent (18)F-NaF PET computed tomography and
were followed up for fatal or nonfatal myocardial infarc
182 on delivery in Sweden from 1973 to 2015, who
were followed up for IHD through the end of 2015.
183 Participants
were followed up for kidney failure (defined as the init
184 weden during 1973 to 1995 (48.6% women), who
were followed up for lipid disorders identified from nat
185 Of the 1585 patients, 1175
were followed up for more than 1 year after PVI.
186 ebirths in Sweden between 1973 and 2015, who
were followed up for mortality through Dec 31, 2017 (max
187 They
were followed up for over 48 months for function of the
188 Women and men
were followed up for recurrent MI, recurrent CHD events
189 Those with P <= 5 x 10(-6)
were followed up for replication in 1697 asthmatic patie
190 of ICS response described in published GWAS
were followed up for replication in the admixed populati
191 Infants
were followed up for safety until 9 months of age.
192 , 1997, who had gestational age data and who
were followed up for survival and comorbidities through
193 rt disease), valvular, and end-organ disease
were followed up for the adverse composite outcome of de
194 ts with NSTI at a quaternary referral center
were followed up for the outcomes of death, limb loss, a
195 types for celiac disease and type 1 diabetes
were followed up for up to 20 years for development of t
196 of the 12-month study, a subset of patients
were followed up for up to 24 months.
197 2156 (97%) women
were followed up for up to 3 years or up to Jan 1, 2019,
198 probation) from 2011-2012 in the Netherlands
were followed up for violent and any reoffending over 2
199 eft-sided IE who had an (18)F-FDG PET/CT and
were followed-up for 1 year.
200 Participants
were followed-up for 2 years, with a mean of 6.4 visits
201 tomography angiography of 1,769 patients who
were followed-up for 5 years.
202 Participants
were followed-up for a mean of 7.5 years.
203 Overall, 309 SOT recipients
were followed-up for a median of 1000 days from transpla
204 (inpatients, n = 210; outpatients, n = 105)
were followed-up for at least 2 weeks to record disease
205 Participants
were followed-up for CVD mortality after linkage to nati
206 All participants
were followed-up for medically certified cardiac events
207 Patients
were followed-up,
for three years.
208 Each cohort
was followed up from 4th to 12th grade (8 years): 1993-2
209 We included 3779 children who
were followed up from 1970 onwards, and had at least one
210 en from Health Professionals Follow-Up Study
were followed up from 1984 to 2012 and from 1986 to 2010
211 ntal information from national registers who
were followed up from birth throughout 2014.
212 A total of 324 healthy infants
were followed up from birth to age 3 years.
213 members of the New Zealand Dunedin Study who
were followed up from birth until ages 18 and 38 years,
214 rdiovascular Risk in YFS (Young Finns Study)
were followed up from childhood (age 3-18 years) to adul
215 Patients
were followed up from reduced kidney function threshold
216 ed data from 273 pregnant Beninese women who
were followed-up from preconception to delivery.
217 Subsequently, 16 sequence variants
are followed up in a diverticular disease sample from De
218 and December 2016, with the last participant
being followed up in December 2017.
219 e participants (age, >/=40 years; 2006-2008)
were followed up in 2011 through 2013, and 1901 of 3280
220 These findings
were followed up in a specifically selected cohort, in w
221 Promising association signals
were followed up in additional data sets (of 14,545 or 7
222 Findings
were followed up in an additional 23,262 cases and 38,29
223 Novel gene-based associations
were followed up in an independent sample of 233,898 sub
224 ide polymorphisms (SNPs) with p < 1 x 10(-4)
were followed up in an independent sample of 2408 PD pat
225 e randomized controlled study and thereafter
were followed up in ordinary clinical practice were coll
226 Individuals
were followed up in the nationwide Psychiatric Central R
227 mycophenolate mofetil, 1 g twice daily, and
were followed up monthly for 6 months.
228 VD, which suggests that these persons should
be followed up more closely to prevent CVD.
229 Patients
were followed up on days 1, 7, and 28 and then every 2 m
230 Children recruited from the MCS have
been followed up over six recruitment sweeps to date at
231 1634 patients with chronic anterior uveitis
were followed up over 7936 eye-years (4676 person-years)
232 All patients
were followed up over a 1-year period (study end date, M
233 Sept 30, 2012, 2 010 398 cohort participants
were followed up over a median of 8.52 years (IQR 8.05-8
234 ond extensively drug-resistant tuberculosis,
were followed up over a period of 6 years.
235 Among 329 survivors who
were followed-up over a median of 52 months, blood eosin
236 (IA-2A), or a combination of these, and they
were followed up prospectively at 3- to 6-month interval
237 Data on deceased patients who initially
were followed up prospectively in the randomized control
238 seholds within 3 different regions of Uganda
were followed up prospectively.
239 n with EV-A71 neurological disease who could
be followed up showed complete recovery by 1-2 months.
240 roup and 29 698 (89.1%) in the control group
were followed up successfully.
241 ng their first examination in 1971-1975) who
were followed up through December 2015.
242 January 1, 2008, and December 31, 2012, and
were followed up through December 31, 2013.
243 surements and no CVD at baseline (1992-1995)
were followed up through December 31, 2018.
244 Patients
were followed up through January 2018.
245 Patients
were followed up through to Dec 31, 2014.We assessed the
246 oyment or full-time education before injury,
were followed-up through telephone interview at 6, 12, 2
247 the basis of data from 213 patients who had
been followed up to autopsy and met inclusion criteria o
248 a and Intrauterine Growth Restriction) study
were followed up to 10.8 years.
249 Patients
were followed up to 15 months after ablation.
250 ts (90%), 17 (3.9%) withdrew, and all others
were followed up to 3 months.
251 Patients (n = 1,484)
were followed up to 41 d after admission (median, 8 d),
252 patients were included in this study and 54
were followed up to 6 months.
253 ctive cohort study between 2006 and 2009 and
were followed up to 7 years until <=2015.
254 Participants
were followed up to 76 weeks after final injection.
255 ve between 2009 to 2017 without a prior ICD,
were followed up to 90 days.
256 All participants
were followed up to day 85.
257 t between Jan 1, 2007, and Dec 31, 2013, and
were followed up to Dec 31, 2014 (end of study).
258 ed between September and December, 2016, who
were followed up to detect whether they developed cutane
259 Patients
were followed up to postoperative month 3 (POM3).
260 over the stroke-affected gastrocnemius) and
were followed up to poststroke d 14.
261 ients without pre-event dementia, 1982 (95%)
were followed up to the end of study or death.
262 tudy drugs from age 8 weeks to 24 months and
were followed-up to age 36 months.
263 agnoses of both outcomes on 1 April 2001 and
was followed up until 31 March 2015.
264 The cohort
was followed up until Dec 31, 2011.
265 VD) and cancer in 1980 (women) or 1986 (men)
were followed up until 2012.
266 d the UK Biobank study from 2006 to 2010 and
were followed up until 2016 or 2017.
267 data between 2006 and 2010, and participants
were followed up until 2016.
268 Patients
were followed up until 31 July 2017.
269 Patients
were followed up until death or July 31, 2018 (date of l
270 Patients with type 1 diabetes mellitus
were followed up until death or study end on December 31
271 Patients
were followed up until death or study end.
272 Patients
were followed up until death or were censored on Decembe
273 All patients who had surgery
were followed up until Dec 31, 2017.
274 Nutrition Examination Survey (1988 to 1994)
were followed up until December 31, 2011.
275 Patients
were followed up until discharge.
276 Participants
were followed up until Jan 1, 2017 for cause-specific mo
277 Subsequently, participants
were followed up until January 1, 2015, for the onset of
278 y 26, 2006, we identified 2666 contacts, who
were followed up until March 1, 2016.
279 Patients
were followed up until membership termination, death, or
280 Patients
were followed up until October 1, 2017, and deaths were
281 Individuals
were followed up until onset of mental illness, death, e
282 Survivors
were followed up until Sept 30, 2016, and deaths up to t
283 Patients
were followed up until the earliest occurrence of a card
284 verse Events of Anti-HIV Drugs (D:A:D) study
were followed up until the earliest occurrence of CKD, t
285 The imaging characteristics
were followed up until the occurrence of PML-IRIS.
286 Patients
were followed up until they could perform chart visual a
287 nese (50+ years) recruited from 2003 to 2008
were followed-up until 2017.
288 Patients
were followed-up until discharge from hospital for a med
289 Participants
were followed up using both DUS and CTA in a mutually bl
290 A total of 418,057 adults
were followed-up using a nationwide prospective cohort s
291 Patients
were followed-up weekly for 42 days.
292 gible patients (308 patients [96.9%] of whom
were followed up)
were older and had more advanced disea
293 from European ancestry datasets will need to
be followed-up with more diverse data.
294 al Province (population 224 000), Sri Lanka,
were followed up with a self-harm surveillance system, e
295 we included all consenting participants who
were followed up with completed pregnancies at trial end
296 These binding studies
were followed up with in silico binding studies of lanos
297 Participants
were followed up with repeated measurements of depressiv
298 Subjects
were followed up with visits occurring every 6 months fo
299 The animals
were followed-up with serial MRI, PET scans, and histolo
300 Of 26 patients who
were followed up within 2 weeks, despite clinical and ra